Targeting the Notch ligand jagged1 in both tumor cells and stroma in ovarian cancer

Clinical Cancer Research

Volumn 17, Issue 17, 2011, Pages 5674-5685

  Steg, Adam D ^a   Katre, Ashwini A ^a   Goodman, Blake ^b   Han, Hee Dong ^b   Nick, Alpa M ^b   Stone, Rebecca L ^b   Coleman, Robert L ^b   Alvarez, Ronald D ^a   Lopez Berestein, Gabriel ^b   Sood, Anil K ^b   Landen, Charles N ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; JAGGED1; PACLITAXEL; SMALL INTERFERING RNA; SONIC HEDGEHOG PROTEIN; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR GLI2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; DRUG SENSITIZATION; DRUG TARGETING; FEMALE; GENE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MDR1 GENE; MICROVASCULATURE; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRIDGED COMPOUNDS; CALCIUM-BINDING PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; EPITHELIAL CELLS; FEMALE; HEDGEHOG PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MEMBRANE PROTEINS; MICE; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; RECEPTORS, NOTCH; RNA INTERFERENCE; RNA, SMALL INTERFERING; STROMAL CELLS; TAXOIDS; TRANSCRIPTION FACTORS;

EID: 80052451811     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0432     Document Type: Article

References (50)

1. Bhoola S., Hoskins W.J. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 2006;107:1399-1410 (Pubitemid 44336908)
2. Fortini M.E. Notch signaling: The core pathway and its posttranslational regulation. Dev Cell 2009;16:633-647
3. Wang Z., Li Y., Banerjee S., Sarkar F.H. Emerging role of Notch in stem cells and cancer. Cancer Lett 2009;279:8-12.
4. Hopfer O., Zwahlen D., Fey M.F., Aebi S. The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer 2005;93:709-718 (Pubitemid 41486463)
5. Park J.T., Li M., Nakayama K., Mao T.L., Davidson B., Zhang Z., et al. Notch3 gene amplification in ovarian cancer. Cancer Res 2006;66: 6312-6318
6. Choi J.H., Park J.T., Davidson B., Morin P.J., Shih Ie M., Wang T.L. Jagged- 1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res 2008;68:5716-5723
7. Jung S.G., Kwon Y.D., Song J.A., Back M.J., Lee S.Y., Lee C., et al. Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma. Cancer Sci 2010;101:1977-1983
8. Pannuti A., Foreman K., Rizzo P., Osipo C., Golde T., Osborne B., et al. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010;16: 3141-3152
9. Zhang S., Balch C., Chan M.W., Lai H.C., Matei D., Schilder J.M., et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008;68:4311-4320
10. Park J.T., Chen X., Trope C.G., Davidson B., Shih Ie M., Wang T.L. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol 2010;177:1087-1094
11. Lu C., Bonome T., Li Y., Kamat A.A., Han L.Y., Schmandt R., et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007;67:1757-1768 (Pubitemid 46383403)
12. Yan M., Plowman G.D. Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res 2007;13:7243-7246
13. Phng L.K., Gerhardt H. Angiogenesis: A team effort coordinated by notch. Dev Cell 2009;16:196-208.
14. Li J.L., Harris A.L. Notch signaling from tumor cells: A new mechanism of angiogenesis. Cancer Cell 2005;8:1-3. (Pubitemid 40991807)
15. LaVoie M.J., Selkoe D.J. The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gammasecretase and release signaling fragments. J Biol Chem 2003;278: 34427-34437 (Pubitemid 37553289)
16. Ascano J.M., Beverly L.J., Capobianco A.J. The C-terminal PDZ-ligand of JAGGED1 is essential for cellular transformation. J Biol Chem 2003;278:8771-8779 (Pubitemid 36800634)
17. Buick R.N., Pullano R., Trent J.M. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985;45:3668-3676 (Pubitemid 15226443)
18. Yoneda J., Kuniyasu H., Crispens M.A., Price J.E., Bucana C.D., Fidler I.J. Expression of angiogenesis-related genes and progression ofhuman ovarian carcinomas in nude mice. J Natl Cancer Inst 1998;90:447-454 (Pubitemid 28160636)
19. Duan Z., Feller A.J., Toh H.C., Makastorsis T., Seiden M.V. TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene 1999;229:75-81. (Pubitemid 29148309)
20. Langley R.R., Ramirez K.M., Tsan R.Z., Van Arsdall M., Nilsson M.B., Fidler I.J. Tissue-specific microvascular endothelial cell lines from H-2K(b)- tsA58 mice for studies of angiogenesis and metastasis. Cancer Res 2003;63:2971-2976 (Pubitemid 36667171)
21. Steg A., Wang W., Blanquicett C., Grunda J.M., Eltoum I.A., Wang K., et al. Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn 2006;8:76-83. (Pubitemid 43257437)
22. Landen C.N. Jr, Lu C., Han L.Y., Coffman K.T., Bruckheimer E., Halder J., et al. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 2006;98: 1558-1570 (Pubitemid 44680907)
23. Straetemans R., O'Brien T., Wouters L., Van Dun J., Janicot M., Bijnens L., et al. Design and analysis of drug combination experiments. Biom J 2005;47:299-308. (Pubitemid 40977269)
24. Han H.D., Mangala L.S., Lee J.W., Shahzad M.M., Kim H.S., Shen D., et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res 2010;16:3910-3922
25. Lu C., Han H.D., Mangala L.S., Ali-Fehmi R., Newton C.S., Ozbun L., et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010;18: 185-197
26. Kim S.J., Uehara H., Karashima T., Shepherd D.L., Killion J.J., Fidler I.J. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 2003;9:1200-1210 (Pubitemid 36323730)
27. Baker C.H., Kedar D., McCarty M.F., Tsan R., Weber K.L., Bucana C.D., et al. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 2002;161:929-938 (Pubitemid 34988380)
28. Cai Y.Q., Chen S.R., Han H.D., Sood A.K., Lopez-Berestein G., Pan H.L. Role of M2, M3, and M4 muscarinic receptor subtypes in the spinal cholinergic control of nociception revealed using siRNA in rats. J Neurochem 2009;111:1000-1010
29. Feng S., Agoulnik I., Truong A., Li Z., Creighton C.J., Kaftanovskaya E.M., et al. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer 2010;17: 1021-1033
30. Landen C.N., Goodman B.W., Katre A.A., Steg A.D., Nick A.M., Stone R., et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 2010;9:3186-3199
31. Rodilla V., Villanueva A., Obrador-Hevia A., Robert-Moreno A, Fernandez- Majada V, Grilli A, et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci U S A 2009;106:6315-6320
32. Schreck K.C., Taylor P., Marchionni L., Gopalakrishnan V., Bar E.E., Gaiano N., et al. The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: A potential mechanism of therapeutic resistance. Clin Cancer Res 2010;16:6060-6070
33. + cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010;29:2672-2680
34. Katas H., Alpar H.O. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release 2006;115:216-225 (Pubitemid 44559708)
35. Liu X., Howard K.A., Dong M., Andersen M.O., Rahbek U.L., Johnsen M.G., et al. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 2007;28:1280-1288 (Pubitemid 44816373)
36. Wong G.T., Manfra D., Poulet F.M., Zhang Q., Josien H., Bara T., et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004;279:12876-12882 (Pubitemid 38445862)
37. Jundt F., Probsting K.S., Anagnostopoulos I., Muehlinghaus G., Chatterjee M., Mathas S., et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004;103:3511-3515 (Pubitemid 38525685)
38. Zeng Q., Li S., Chepeha D.B., Giordano T.J., Li J., Zhang H., et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 2005;8:13-23. (Pubitemid 40991811)
39. Zimrin A.B., Pepper M.S., McMahon G.A., Nguyen F., Montesano R., Maciag T. An antisense oligonucleotide to the notch ligand jagged enhances fibroblast growth factor-induced angiogenesis in vitro. J Biol Chem 1996;271:32499-32502 (Pubitemid 27008662)
40. Crosnier C., Attie-Bitach T., Encha-Razavi F., Audollent S., Soudy F., Hadchouel M., et al. JAGGED1 gene expression during human embryogenesiselucidates the wide phenotypic spectrum of Alagille syndrome. Hepatology 2000;32:574-581
41. Merchant A.A., Matsui W. Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res 2010;16:3130-3140
42. Takahashi-Yanaga F., Kahn M. Targeting Wnt signaling: Can we safely eradicate cancer stem cells?Clin Cancer Res 2010;16:3153-3162
43. Rizzo P., Osipo C., Foreman K., Golde T., Osborne B., Miele L. Rational targeting of Notch signaling in cancer. Oncogene 2008;27:5124-5131
44. Katoh M., Notch ligand, JAG1, is evolutionarily conserved target of canonical WNT signaling pathway in progenitor cells. Int J Mol Med 2006;17:681-685
45. Chen X., Stoeck A., Lee S.J., Shih I.M., Wang M.M., Wang T.L. Jagged1 expression regulated by Notch3 and Wnt/β-catenin signaling pathways in ovarian cancer. Oncotarget 2010;1:210-218
46. Sims-Mourtada J., Izzo J.G., Ajani J., Chao K.S. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 2007;26:5674-5679 (Pubitemid 47267845)
47. Narita S., So A., Ettinger S., Hayashi N., Muramaki M., Fazli L., et al. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin Cancer Res 2008;14:5769-5777
48. Mine T., Matsueda S., Gao H., Li Y., Wong K.K., Peoples G.E., et al. Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells. Oncol Rep 2010;23:1537-1543
49. Mimeault M., Johansson S.L., Henichart J.P., Depreux P., Batra S.K. Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. Mol Cancer Ther 2010;9:617-630
50. Ulasov I.V., Nandi S., Dey M., Sonabend A.M., Lesniak M.S. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133 (+) glioma stem cells to temozolomide therapy. Mol Med 2010;17: 103-112